Manufacture of 200 GN of cgmp PTH-IA

Ended Awarded Last action

Contract number
75N95020F00001
Awardee
Awarding agency
Obligated
$1,008,668

Award facts

Contract value 96% obligated
  • $1,008,667.73 Current, with exercised options
  • $1,049,589.73 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Torrance, CA 90505, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00007 · HHS UDO sprint exercise - to administrate DE-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 -$450
Terminate for Convenience P00006 · EOI:: implementing the presidents department of government efficiency cost efficiency initiative (march 19, 2025)::EOI notice of termination for convenience… $0
Supplemental Agreement for work within scope P00005 · Have bachem issue QA reviewed coas of GMP drug substance PTH-IA and its qualitative reference standard and assign a new retest date based on the stability study… $28,500
Supplemental Agreement for work within scope P00004 $109,900
Supplemental Agreement for work within scope P00003 $35,000
Supplemental Agreement for work within scope P00002 $30,300
Supplemental Agreement for work within scope P00001 · Manufacture of 200 GN of cgmp PTH-IA. POP: 8/4/2020 - 8/3/2024. Modification P00001 is to provide part of the non-GMP pilot lot as an accelerated sample. $5,850
Original award $799,568

About this award

Written by GovTribe AI ·

The National Institute on Drug Abuse issued a delivery order to Bachem Americas Inc. on August 4, 2020, under the "CRO Support for NCATS Drug Substance Development and Manufacture" IDIQ for manufacturing 200 grams of cGMP parathyroid hormone-related protein (PTH-IA) and associated contract research organization support for the National Center for Advancing Translational Sciences drug substance development program.

The order carries a ceiling value of $1,049,589.73 and is priced on a firm fixed price basis. Place of performance is Torrance, California. The ultimate completion date is May 1, 2025. This delivery order was issued as part of an HHS Unique Distribution Organization SPRINT exercise to de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) in preparation for the September 30, 2026, closing of the period of availability for those funds. No set-aside was used.

Quick answers

Who was awarded contract 75N95020F00001?

75N95020F00001 was awarded to Bachem Americas Inc. by National Institute on Drug Abuse (National Institutes of Health) on August 4, 2020.

How much is contract 75N95020F00001 worth?

The government has obligated $1,008,668 on 75N95020F00001. Its potential value, with all options, is $1,049,590.

Is contract 75N95020F00001 an order under another contract?

Yes. 75N95020F00001 is a delivery order under HHSN271201700009I, an indefinite delivery contract, on CRO Support for NCATS Drug Substance Development and Manufacture.

Was contract 75N95020F00001 competed?

The extent of competition for 75N95020F00001 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login